NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-GM-18-022 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-055 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-757 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of activities aimed at broadening the training experience to better prepare individuals for careers in the biomedical research workforce.).
Funding Opportunity PA-18-756 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded predoctoral T32 training grants. These funds are designed to provide support for the development and implementation of curricular or training activities aimed at providing graduate trainees with a strong foundation in areas related to conducting rigorous and transparent research to enhance reproducibility in the biomedical sciences.
Notice NOT-NS-18-059 from the NIH Guide for Grants and Contracts
Notice NOT-AT-18-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-066 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-067 from the NIH Guide for Grants and Contracts
Notice NOT-DE-19-018 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-620 from the NIH Guide for Grants and Contracts
Notice NOT-AG-18-008 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-031 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-017 from the NIH Guide for Grants and Contracts
Notice NOT-GM-18-027 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-619 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-027 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-063 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-752 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement (FOA) from the National Cancer Institute (NCI) is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the NCI created the Drug Resistance and Sensitivity Network (DRSN), a collaborative network of centers of excellence (supported by U54 cooperative agreement awards) focused on using advanced techniques and models to accelerate understanding of issues of cancer resistance or extreme sensitivity to anticancer agents. The DRSN was also developed to assist in issues of cancer drug resistance in the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical industry partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-U54 investigators and DRSN U54-supported investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel discoveries in cancer drug resistance that could ultimately be tested in NCI-sponsored clinical trials.
Funding Opportunity PA-18-751 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support aging research that addresses disparities in health, with emphasis on geriatrics and clinical gerontology studies.
Funding Opportunity PA-18-753 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections.